Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Developer of surgical and diagnostic products announces financial results
December 12th, 2004
Neoprobe Corporation (OTCBB:NEOP) announced consolidated operating results for the third quarter of 2004. Third quarter results included revenues of $1.7 million, representing increases of 46% compared to $1.2 million for the third quarter of 2003 and 11% compared to $1.5 million for the second quarter of 2004. In addition, Neoprobe reported a net loss of $239,000 or $0.00 per share for the third quarter of 2004 compared to a loss of $659,000 or $0.02 per share for the same period in 2003. The smaller operating loss in the third quarter represented an improvement of 64% compared to third quarter 2003. Total operating expenses were $1.3 million for...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
